242 related articles for article (PubMed ID: 22266832)
1. Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population.
Chaar I; Arfaoui TA; El Amine el HO; Mahmoud LB; Khiari M; Sammoud S; Lounis A; Amara S; Gharbi L; Hmida AB; Mzabi S; Bouraoui S
Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):320-7. PubMed ID: 22266832
[TBL] [Abstract][Full Text] [Related]
2. Relationship between MDM2 and p53 alterations in colorectal cancer and their involvement and prognostic value in the Tunisian population.
Chaar I; Amara S; Khiari M; Ounissi D; Dhraif M; Ben Hamida AE; Gharbi L; Mzabi S; Bouraoui S
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):228-36. PubMed ID: 22914606
[TBL] [Abstract][Full Text] [Related]
3. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
4. Prognostic potential of the MDM2 309T>G polymorphism in stage I lung adenocarcinoma.
Enokida Y; Shimizu K; Atsumi J; Kakegawa S; Takase Y; Kaira K; Yashima H; Araki T; Nakazawa S; Ohtaki Y; Nagashima T; Alexander L; Usui K; Ishikawa T; Hayashizaki Y; Takeyoshi I
Cancer Med; 2016 Aug; 5(8):1791-801. PubMed ID: 27228500
[TBL] [Abstract][Full Text] [Related]
5. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
6. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
7. Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.
Renouf DJ; Zhai R; Sun B; Xu W; Cheung WY; Heist RS; Kulke MH; Cescon D; Asomaning K; Marshall AL; Li S; Christiani DC; Liu G
J Gastroenterol Hepatol; 2013 Sep; 28(9):1482-8. PubMed ID: 23735059
[TBL] [Abstract][Full Text] [Related]
8. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
Hori Y; Miyabe K; Yoshida M; Nakazawa T; Hayashi K; Naitoh I; Shimizu S; Kondo H; Nishi Y; Umemura S; Kato A; Ohara H; Inagaki H; Joh T
PLoS One; 2015; 10(3):e0118829. PubMed ID: 25734904
[TBL] [Abstract][Full Text] [Related]
9. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status.
Menin C; Scaini MC; De Salvo GL; Biscuola M; Quaggio M; Esposito G; Belluco C; Montagna M; Agata S; D'Andrea E; Nitti D; Amadori A; Bertorelle R
J Natl Cancer Inst; 2006 Feb; 98(4):285-8. PubMed ID: 16478747
[TBL] [Abstract][Full Text] [Related]
10. MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.
Hofstetter G; Berger A; Bauer EM; Schuster E; Wolf A; Chamson M; Müller-Holzner E; Reimer D; Braicu EI; Sehouli J; Ulmer H; Cacsire Castillo-Tong D; Zeillinger R; Concin N
Oncol Rep; 2012 Mar; 27(3):673-7. PubMed ID: 22134502
[TBL] [Abstract][Full Text] [Related]
11. Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309 T>G gene variants act on colorectal cancer development or progression?
Tuna G; Küçükhüseyin O; Arıkan S; Kaytan Sağlam E; Güler E; Cacına C; Oztop O; Turan S; Korkmaz G; Yaylım I
DNA Cell Biol; 2013 Jul; 32(7):400-8. PubMed ID: 23777425
[TBL] [Abstract][Full Text] [Related]
12. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
[TBL] [Abstract][Full Text] [Related]
13. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
14. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
Ohmiya N; Taguchi A; Mabuchi N; Itoh A; Hirooka Y; Niwa Y; Goto H
J Clin Oncol; 2006 Sep; 24(27):4434-40. PubMed ID: 16983111
[TBL] [Abstract][Full Text] [Related]
15. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Walsh CS; Miller CW; Karlan BY; Koeffler HP
Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
[TBL] [Abstract][Full Text] [Related]
16. p53 and mdm2 expression in colorectal carcinoma: a correlative analysis with clinical staging and histological parameters.
Das P; Vaiphei K; Jain D; Wig JD
Int J Surg Pathol; 2007 Oct; 15(4):335-45. PubMed ID: 17913939
[TBL] [Abstract][Full Text] [Related]
17. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.
Zhang X; Pageon L; Post SM
Oncogene; 2015 Aug; 34(33):4412-20. PubMed ID: 25435368
[TBL] [Abstract][Full Text] [Related]
18. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
[TBL] [Abstract][Full Text] [Related]
19. Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy.
Shinohara A; Sakano S; Hinoda Y; Nishijima J; Kawai Y; Misumi T; Nagao K; Hara T; Matsuyama H
Cancer Sci; 2009 Dec; 100(12):2376-82. PubMed ID: 19764997
[TBL] [Abstract][Full Text] [Related]
20. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
